Dianthus Therapeutics, Inc. /DE/ (DNTH) Stock Price, Financials & Summary

Price chart

Oct 8Oct 13Oct 16Oct 21Oct 26Oct 29Nov 3Nov 6

Key dataNov 6, 2026

Open$84.12

From 52W high−25.81%

Volume593970.00

Market cap$4.84B

P/E (TTM)2867.7x

P/S (TTM)1782.4x

Div yield—

Key dataNov 6, 2026

Open

$84.12

From 52W high

−25.81%

Volume

593970.00

Market cap

$4.84B

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−101.7x

P/E (TTM)

2867.7x

RSI (14)

53.0

MomentumView details →

1D Return

+3.64%

YTD Return

+106.34%

SummaryUpdated Sep 1, 2026

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) is a clinical-stage biotechnology company founded in 2015 and headquartered in New York, New York. The company went public in June 2018 and focuses on developing novel monoclonal antibody treatments for patients suffering from severe autoimmune and inflammatory diseases. Dianthus is currently advancing its lead drug candidate, DNTH103, through Phase 1 clinical trials for multiple neurological conditions including generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.

Ask drillr about Dianthus Therapeutics, Inc. /DE/ →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

2867.7x

EV/EBITDA

−101.7x

EV/Sales

1474.6x

P/S (TTM)

1782.4x

P/B (TTM)

3.9x

ProfitabilityView details →

Gross Margin

97.20%

Net Margin

−1463.83%

EBITDA Margin

−1449.52%

ROE (TTM)

−3.20%

ROA (TTM)

−3.12%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

−11.70%

EPS YoY

+100.86%

FCF YoY

−60.41%

Revenue CAGR 3Y

−31.80%

EPS CAGR 3Y

−64.71%

EBITDA YoY

+69.56%

MomentumView details →

1D Return

+3.64%

YTD Return

+106.34%

1Y Return

+134.38%

RSI (14)

53.0

vs 50D SMA

−5.55%

vs 200D SMA

−1.06%

Capital & dividendView details →

Debt/Equity

0.00x

Current Ratio

30.02x

Quick Ratio

30.02x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.81

EPS Surprise

14.24%

Beats (12Q)

4/12

Next Q EPS Est

−$1.07

Avg Surprise (4Q)

−1.73%

Rev Surprise

162.51%

Financials snapshotView financials →

Revenue (TTM)

2.72M

Net Income (TTM)

−39.79M

Op. CF (TTM)

−175.15M

Next earningsMar 8, 2027 →

Latest newsMore news →

Dianthus Therapeutics reported a third-quarter loss of $0.81 per share, compared with a loss of $0.97 per share a year earlier.3d ago

Dianthus Therapeutics is advancing DNTH312, a first-in-class bifunctional fusion protein, aiming to be Phase 1 ready by year-end 2027.95d ago

Similar companies

CRISPR Therapeutics AGCRSP Travere Therapeutics, Inc.TVTX Edgewise Therapeutics, Inc.EWTX Erasca, Inc.ERAS Lepu Biopharma Co., Ltd.02157.HK CK Life Sciences Int'l., (Holdings) Inc.00775.HK Find similar companies →

Latest newsMore news →

Dianthus Therapeutics reported a third-quarter loss of $0.81 per share, compared with a loss of $0.97 per share a year earlier.3d ago Dianthus Therapeutics is advancing DNTH312, a first-in-class bifunctional fusion protein, aiming to be Phase 1 ready by year-end 2027.95d ago